Aids activists are angry about the government's indecision over providing anti-Aids drugs and look set to resume their civil disobedience campaign. A final decision about returning to civil disobedience could be made at the Treatment Action Campaign's (TAC) national congress, which is to be held in Durban within the next two weeks. Provincial meetings ahead of the congress have already voted overwhelmingly in favour of a return to the disobedience campaign, which was suspended in April after a meeting between TAC representatives and Deputy President Jacob Zuma.
Equity in Health
Aids protest poised to resume in South Africa
Applying an equity lens to child health and mortality: more of the same is not enough
Gaps in child mortality between rich and poor countries are unacceptably wide and in some areas are becoming wider, as are the gaps between wealthy and poor children within most countries. Poor children are more likely than their better-off peers to be exposed to health risks, and they have less resistance to disease because of undernutrition and other hazards typical in poor communities. Regular monitoring of inequities and use of the resulting information for education, advocacy, and increased accountability among the general public and decision makers is urgently needed, but will not be sufficient. Equity must be a priority in the design of child survival interventions and delivery strategies, and mechanisms to ensure accountability at national and international levels must be developed.
creative routes used to supply arv's
Not-for-profit groups and some individuals are using "creative routes" to provide antiretroviral drugs to HIV-positive people in developing countries, the New York Times reports. Some organisations channel unused medications from U.S. patients who have changed medications, taken a break from treatment or died to patients in developing countries, and other organisations purchase low-cost generic versions of the drugs in other countries and import them, sometimes illegally, into neighbouring countries.
Data collection an effective weapon in anti-HIV/AIDS arsenal in Swaziland
A new information gathering programme will soon provide an essential database of medical and other humanitarian needs in the agricultural heart of Swaziland to fill gaps in the national records and bring much needed insight into how to best counter the spread of HIV/AIDS.
Frustration over delay in namibian drug roll-out
Frustration is mounting among activists over the Namibian government's delay in providing anti-AIDS drugs to its HIV-positive citizens. The government announced in April this year that it had budgeted US $10.9 million for the purchase of antiretroviral (ARV) drugs for HIV-positive people. But while the health ministry has on numerous occasions indicated their intention to provide treatment, this had not been translated into action, activists told PlusNews.
GLOBAL AIDS FUND FACES SERIOUS SHORTFALL
The cash-strapped Global Fund to fight HIV/AIDS, Tuberculosis (TB) and Malaria fell under the spotlight in July, when ministers from 14 countries met in Paris, France, to address the fund's financial woes. The fund, which has committed US $1.5 billion to programmes in 92 countries in the last 18 months, faces a lack of money for proposals waiting to be funded in October.
HIV/AIDS FUNDING STILL FALLS SHORT OF PROJECTED NEED, UNAIDS REPORT SAYS
Governments, international organisations, foundations and nongovernmental organisations in 2003 will spend an estimated $4.7 billion to address the AIDS epidemic in low- and middle-income countries, but that amount is less than half of the more than $10.5 billion that will be needed each year by 2005 to fight the epidemic in those countries, according to a new UNAIDS report.
Mapping out a treatment programme in malawi
The World Health Organisation (WHO) presented a challenge to African countries last year by setting a target of three million HIV-positive Africans to be on antiretroviral (ARV) HIV/AIDS therapy by 2005. Almost a year later, a workshop on scaling up access to care and treatment for people living with HIV/AIDS (PWAs) in 17 East and Southern African countries has been held to assist them in reaching that goal. HIV/AIDS programme managers and health officials from the 17 countries emerged with country-specific "road maps" to guide them in expanding their treatment programmes.
THE NEW PLAGUE CZAR
Just a few days before his visit to Africa, President Bush announced that Randall Tobias, the former chairman and CEO of Eli Lilly Co., will take the new position of "Czar" in charge of U.S. global HIV/AIDS funding. The move to position a drug company executive centrally in global health policymaking is nothing new for this administration, but the openness of this gesture to the industry suggests that there is little shame in reversing the progress of the last several years, particularly in the realm of medicine treatment access, says this commentary on the web site www.zmag.org
TUBERCULOSIS, PUBLIC HEALTH AND THE NEED FOR ARVS
Tuberculosis remains the single greatest public health challenge associated with HIV worldwide. Despite widespread recognition of this fact, and clinical trials showing that interventions can help few programmes exist to implement such measures, according to a view presented at the International Aids Society Conference in Paris in July.